Eleven is a biologics oncology company focused on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics (TPTs).
Our most advanced TPTs are in clinical development for cancers which have significant unmet needs for patients. Vicinium™ is in an active Phase 3 clinical trial in the U.S. and Canada for the treatment of high-grade non-muscle invasive bladder cancer. Proxinium™ is being developed for late stage squamous cell carcinoma of the head and neck, preparing for a Phase 2 clinical trial in combination with cancer immunotherapy.